Therefore, we aimed to investigate factors that can predict fibrosis progression in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) with ALT levels ≤ 30 U/L. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.